A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury.
In preclinical stages of drug development, anticipating potential adverse drug effects such as toxicity is an important issue for both saving resources and preventing public health risks. Current in vitro cytotoxicity tests are restricted by their predictive potential and their ability to provide mechanistic information. This study aimed to develop a metabolomic mass spectrometry-based approach for the detection and classification of drug-induced hepatotoxicity. To this end, the metabolite profiles of human derived hepatic cells (i.e., HepG2) exposed to different well-known hepatotoxic compounds acting through different mechanisms (i.e., oxidative stress, steatosis, phospholipidosis, and controls) were compared by multivariate data analysis, thus allowing us to decipher both common and mechanism-specific altered biochemical pathways. Briefly, oxidative stress damage markers were found in the three mechanisms, mainly showing altered levels of metabolites associated with glutathione and γ-glutamyl cycle. Phospholipidosis was characterized by a decreased lysophospholipids to phospholipids ratio, suggestive of phospholipid degradation inhibition. Whereas, steatosis led to impaired fatty acids β-oxidation and a subsequent increase in triacylglycerides synthesis. The characteristic metabolomic profiles were used to develop a predictive model aimed not only to discriminate between non-toxic and hepatotoxic drugs, but also to propose potential drug toxicity mechanism(s).
Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria - Fundación Hospital La Fe, Valencia, Spain. CIBERehd, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, FIS, Spain.|Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Valencia, Spain.
Juan Carlos
JC
García-Cañaveras
Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria - Fundación Hospital La Fe, Valencia, Spain. CIBERehd, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, FIS, Spain.|Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Valencia, Spain.
José V
JV
Castell
Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria - Fundación Hospital La Fe, Valencia, Spain. CIBERehd, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, FIS, Spain.|Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Valencia, Spain.
M Teresa
MT
Donato
Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria - Fundación Hospital La Fe, Valencia, Spain. CIBERehd, Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas, FIS, Spain.
Agustín
A
Lahoz
D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism*; D005234:Fatty Liver / Q000139:chemically induced / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism; D056945:Hep G2 Cells; D006801:Humans; D013058:Mass Spectrometry; D055432:Metabolomics / Q000379:methods*; D008954:Models, Biological; D018384:Oxidative Stress; D010743:Phospholipids / Q000737:chemistry
D010743:Phospholipids; D005978:Glutathione